(Date:9/4/2008)... may be shortchanging their golden years by tappin...iversity of Illinois expert who has studied the fe..., More than three of every four Americans trim th...iming benefits early, a choice many might forego i... consequences, law professor Richard L. Kaplan say...
(Date:9/4/2008)...ncology contract research organization, has publis...uanced Approach to Get Into the Clinic Faster.&quo...al research scientist with 35 years of experience,...mmonly viewed as straightforward investigations ru...rue integration with preclinical, regulatory and c...
(Date:9/4/2008)...NORWICH, England and ONGAR, Ireland,Sept. 4 /PRNe...ofield Media,Europe Ltd, announced on the 29th Aug... publication from Silverdog Publishing., Health a... the iconic,Health and Safety at Work Act 1974 and.... It has been relied upon by blue-chip corporates,...
(Date:9/4/2008)...-FirstCall/ -- ULURU Inc. (Amex:,ULU) today announ...Weisel,Partners Healthcare Conference at 3:15 p.m....out ULURU Inc.:, ULURU Inc. is an emerging specia...ent of a portfolio of wound management, plastic su...nd consumers improved clinical,outcomes through co...
Breaking Medicine News(10 mins):Health News:New guide explores making the most of Social Security 2Health News:New guide explores making the most of Social Security 3Health News:Oncology Clinical Research Scientist Recommends a Nuanced Preclinical Study Process to Speed Drug Development 2Health News:Oncology Clinical Research Scientist Recommends a Nuanced Preclinical Study Process to Speed Drug Development 3Health News:Schofield Publishing Enters the Newsletter Market 2...c Sydney Opera House was added to the list of Worl...truction of Danish architect Jorn Utzon's vision w...w cultural sites given the coveted status by UNESC...ittee, meeting in Christchurch, New Zealand. The ...
...ta, who plays the role of a woman in movie 'Hairsp...him lose weight. The star admits that having to... female character Edna Turnblad in the 2007 remake...turned-movie was the perfect combination to shed t...
...x-girlfriend Kate Middleton's curvaceous figure ha...ays been in style for her slender but athletic fig...In her recent appearances Kate appeared painfully ...y and almost flat chested. And according to specu...
...ent A.P.J. Abdul Kalam Friday called for taking ad...iagnostic tool and of tele-radiology to help the n...e was speaking during a visit to the digital radio...on of India Limited (ECIL), which is working towar...
Other Medicine News:(Date:9/4/2008)...RICH, Switzerland, September 4 /- Axe...trial to assess the safety and tolerability,of a n...vere pulmonary,infection in cystic fibrosis patien...apeutic agent to be delivered directly to the site...pare the effects of two,different doses of the new...
(Date:9/4/2008)...mg cohort demonstrates potent antiviral activity a...profile -, CAMBRIDGE, Mass., Sept. 4 /PRNewswire-...: IDIX ), a biopharmaceutical company engaged,in ...atment of human viral,and other infectious disease...-of-concept study evaluating IDX899, a non-nucleos...
(Date:9/4/2008)...a Announcements Remain on Schedule with Two Abstra...cal Data Release in November 2008, BRIDGEWATER, N...als,Inc., a specialty pharmaceutical company focu...ic disease, today announced the appointment of,Pet...rectors., Peter Garrambone,s career includes more...
(Date:9/3/2008)... says: Wrong Question Asked. Wrong Children Studie... /PRNewswire-USNewswire/ -- A Centers for Disease,...claims there is no link,between the MMR vaccine an...ys this study does nothing to dispel the growing p... raises several questions concerning design,and me...
Breaking Medicine Technology:Cystic Fibrosis Axentis Pharma Initiates Clinical Trial for Lung Infections 2Cystic Fibrosis Axentis Pharma Initiates Clinical Trial for Lung Infections 3Cystic Fibrosis Axentis Pharma Initiates Clinical Trial for Lung Infections 4Idenix Pharmaceuticals Announces Completion of Proof-of-Concept Study for IDX899 in Treatment-Naive HIV-Infected Patients 2Idenix Pharmaceuticals Announces Completion of Proof-of-Concept Study for IDX899 in Treatment-Naive HIV-Infected Patients 3Idenix Pharmaceuticals Announces Completion of Proof-of-Concept Study for IDX899 in Treatment-Naive HIV-Infected Patients 4Aegerion Pharmaceuticals, Inc. adds Peter Garrambone to Board of Directors, Secures Additional Capital for Clinical Trials 2CDC Misses Target With Flawed MMR/Autism Study 2Programmed death boosts business 3232 1Programmed death boosts business 3232 2Genomic Health to Present at Bank of America 2008 Healthcare Conference and 7th Annual JMP Securities Research Conference 18761 1Genomic Health to Present at Bank of America 2008 Healthcare Conference and 7th Annual JMP Securities Research Conference 18761 2VIA Pharmaceuticals to Present at Rodman 26 Renshaw 5th Annual Global Healthcare Conference 5223 1Vion Pharmaceuticals Announces Initiation of Clinical Trial of Cloretazine 28R 29 28VNP40101M 29 in Combination with Cytarabine 2011 1Vion Pharmaceuticals Announces Initiation of Clinical Trial of Cloretazine 28R 29 28VNP40101M 29 in Combination with Cytarabine 2011 2Vion Pharmaceuticals Announces Initiation of Clinical Trial of Cloretazine 28R 29 28VNP40101M 29 in Combination with Cytarabine 2011 3...achieved both primary and secondary endpoints of,s...ed between,valopicitabine and ribavirin ~, CAMBRID... Idenix,Pharmaceuticals, Inc. today announced resu...ple combination therapy, consisting of,valopicitab...treatment of hepatitis C, pegylated interferon and...
....--(BUSINESS WIRE)--Jun 12, 2007 - Geron,Corporati...g,GRN163L, has demonstrated good pharmacokinetics...involving patients with chronic,lymphocytic leukem...n Colowick, M.D., M.P.H., the company,s president,...in Maui, Hawaii., Favorable Pharmacokinetics; Phar...
Other Medicine Technology:Valopicitabine Combined with Standard of Care Cleared Hepatitis C,Virus in 72% of Patients Who Completed 12 Weeks of Treatment in a,Phase II Trial 2Valopicitabine Combined with Standard of Care Cleared Hepatitis C,Virus in 72% of Patients Who Completed 12 Weeks of Treatment in a,Phase II Trial 3Valopicitabine Combined with Standard of Care Cleared Hepatitis C,Virus in 72% of Patients Who Completed 12 Weeks of Treatment in a,Phase II Trial 4Valopicitabine Combined with Standard of Care Cleared Hepatitis C,Virus in 72% of Patients Who Completed 12 Weeks of Treatment in a,Phase II Trial 5Valopicitabine Combined with Standard of Care Cleared Hepatitis C,Virus in 72% of Patients Who Completed 12 Weeks of Treatment in a,Phase II Trial 6Geron's Telomerase Inhibitor Cancer Drug Demonstrates Good,Pharmacokinetics and Tolerability in Phase I/II Trial 2Geron's Telomerase Inhibitor Cancer Drug Demonstrates Good,Pharmacokinetics and Tolerability in Phase I/II Trial 3Geron's Telomerase Inhibitor Cancer Drug Demonstrates Good,Pharmacokinetics and Tolerability in Phase I/II Trial 4Rhoton Curettes, titanium, length 191 mm, straight.
Castroviejo "HM" Micro Needle Holder with Tungsten-Carbide Inserts, with catch. Serrated.
Clinical micro clamps by Acland. Matte finish. It provides impressive security in use, both against slippage and against leakage due to controlled closing force and working grip surface.
Clinical micro clamps by Acland. Matte finish. It provides impressive security in use, both against slippage and against leakage due to controlled closing force and working grip surface.
Medicine Products: